Older, dangerous drivers are a growing problem in the United States. The National Highway Traffic Safety Administration cites that older individuals above the age of 65 make up approximately 16% of all traffic fatalities and 8% of all people injured in traffic crashes. The number of Americans over 65 is expected to rise to as much as 18% of the population in 2030.
A major cause of traffic crashes in older adults is the sharp decline in cognitive function that is common after the age of 50. Symptoms include, but are not limited to, lack of ability to focus, decreased vision, trouble concentrating, and loss of short term memory. These symptoms can often prohibit safe driving among older adults.
Prevagen, the #1-selling brain booster, is proven to improve cognitive function. The Madison Memory Study was a double-blind placebo-controlled study of 218 individuals aged 40 and older, which concluded that Prevagen improved cognitive function in older adults. Prevagen was also proven to improve driving directions recall for 84% of participants in the Prevagen Quality of Life Study.
Quincy Bioscience is sharing the message of improved cognitive function with the attendees of the American Le Mans Series at Road America on August 16 – 18.
To learn more about how Prevagen benefits older adults, visit http://www.prevagen.com.
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin focused on the discovery and development of novel compounds to improve cognitive performance and therapeutics to treat age related memory loss and diseases of aging. The company’s technology focuses on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.